Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Plus Therapeutics Inc’s stock clocked out at $0.62, up 0.96% from its previous closing price of $0.61. In other words, the price has increased by $0.96 from its previous closing price. On the day, 4.81 million shares were traded. PSTV stock price reached its highest trading level at $0.64 during the session, while it also had its lowest trading level at $0.5963.
Ratios:
To gain a deeper understanding of PSTV’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.20 and its Current Ratio is at 1.20. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On March 17, 2025, D. Boral Capital started tracking the stock assigning a Buy rating and target price of $9.
On January 25, 2021, Ladenburg Thalmann started tracking the stock assigning a Buy rating and target price of $8.Ladenburg Thalmann initiated its Buy rating on January 25, 2021, with a $8 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 22 ’25 when Lenk Robert P bought 110,000 shares for $0.49 per share. The transaction valued at 53,779 led to the insider holds 139,327 shares of the business.
Petersen Greg bought 36,666 shares of PSTV for $20,276 on May 15 ’25.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PSTV now has a Market Capitalization of 61544008 and an Enterprise Value of 54695008. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.57 while its Price-to-Book (P/B) ratio in mrq is 18.84. Its current Enterprise Value per Revenue stands at 10.287 whereas that against EBITDA is -4.501.
Stock Price History:
The Beta on a monthly basis for PSTV is 0.80, which has changed by -0.55714285 over the last 52 weeks, in comparison to a change of 0.13837254 over the same period for the S&P500. Over the past 52 weeks, PSTV has reached a high of $2.31, while it has fallen to a 52-week low of $0.16. The 50-Day Moving Average of the stock is 9.22%, while the 200-Day Moving Average is calculated to be -12.30%.
Shares Statistics:
It appears that PSTV traded 22.77M shares on average per day over the past three months and 17559230 shares per day over the past ten days. A total of 92.18M shares are outstanding, with a floating share count of 91.55M. Insiders hold about 7.77% of the company’s shares, while institutions hold 3.19% stake in the company. Shares short for PSTV as of 1759190400 were 16709205 with a Short Ratio of 0.73, compared to 1756425600 on 4661959. Therefore, it implies a Short% of Shares Outstanding of 16709205 and a Short% of Float of 16.85.
Earnings Estimates
The performance of Plus Therapeutics Inc (PSTV) in the stock market is under the watchful eye of 2.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.03 and low estimates of -$0.04.
Analysts are recommending an EPS of between -$0.15 and -$0.33 for the fiscal current year, implying an average EPS of -$0.24. EPS for the following year is -$0.16, with 2.0 analysts recommending between -$0.14 and -$0.17.
Revenue Estimates
In. The current quarter, 4 analysts expect revenue to total $1.5M. It ranges from a high estimate of $3.32M to a low estimate of $189k. As of. The current estimate, Plus Therapeutics Inc’s year-ago sales were $1.46MFor the next quarter, 4 analysts are estimating revenue of $1.62M. There is a high estimate of $3.63M for the next quarter, whereas the lowest estimate is $700k.
A total of 4 analysts have provided revenue estimates for PSTV’s current fiscal year. The highest revenue estimate was $9.4M, while the lowest revenue estimate was $947k, resulting in an average revenue estimate of $4.94M. In the same quarter a year ago, actual revenue was $5.82MBased on 4 analysts’ estimates, the company’s revenue will be $6.34M in the next fiscal year. The high estimate is $12.11M and the low estimate is $4M.
